First Hawaiian Bank Boosts Stock Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

First Hawaiian Bank increased its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 56.2% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 57,550 shares of the biopharmaceutical company’s stock after buying an additional 20,700 shares during the period. First Hawaiian Bank’s holdings in Halozyme Therapeutics were worth $2,751,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently added to or reduced their stakes in the company. Skandinaviska Enskilda Banken AB publ purchased a new position in Halozyme Therapeutics in the 2nd quarter valued at $49,000. GAMMA Investing LLC raised its position in shares of Halozyme Therapeutics by 67.7% in the third quarter. GAMMA Investing LLC now owns 867 shares of the biopharmaceutical company’s stock valued at $50,000 after buying an additional 350 shares during the last quarter. Toth Financial Advisory Corp purchased a new position in shares of Halozyme Therapeutics in the third quarter worth about $57,000. FSC Wealth Advisors LLC acquired a new position in Halozyme Therapeutics during the third quarter worth about $65,000. Finally, Park Place Capital Corp grew its stake in Halozyme Therapeutics by 828.1% during the 3rd quarter. Park Place Capital Corp now owns 1,355 shares of the biopharmaceutical company’s stock valued at $78,000 after acquiring an additional 1,209 shares in the last quarter. Institutional investors and hedge funds own 97.79% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on the company. Cowen restated a “buy” rating on shares of Halozyme Therapeutics in a report on Friday, October 18th. JMP Securities boosted their price objective on Halozyme Therapeutics from $72.00 to $73.00 and gave the stock a “market outperform” rating in a research note on Friday, November 1st. Wells Fargo & Company cut Halozyme Therapeutics from an “overweight” rating to an “equal weight” rating and upped their target price for the company from $58.00 to $62.00 in a report on Monday, October 7th. Piper Sandler lifted their price target on Halozyme Therapeutics from $51.00 to $52.00 and gave the stock a “neutral” rating in a report on Monday, November 4th. Finally, HC Wainwright reissued a “buy” rating and issued a $68.00 price objective on shares of Halozyme Therapeutics in a report on Monday, December 30th. Four investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $61.11.

Insider Activity

In related news, Director Jeffrey William Henderson sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $50.01, for a total value of $500,100.00. Following the sale, the director now owns 43,611 shares of the company’s stock, valued at $2,180,986.11. This trade represents a 18.65 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 2.70% of the company’s stock.

Halozyme Therapeutics Trading Up 5.0 %

Shares of HALO stock opened at $53.76 on Thursday. Halozyme Therapeutics, Inc. has a fifty-two week low of $33.15 and a fifty-two week high of $65.53. The company has a 50 day moving average price of $50.10 and a 200 day moving average price of $54.00. The stock has a market capitalization of $6.84 billion, a P/E ratio of 17.80, a price-to-earnings-growth ratio of 0.44 and a beta of 1.24. The company has a debt-to-equity ratio of 3.32, a quick ratio of 9.15 and a current ratio of 10.36.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.